TriSalus Life Sciences, Inc. beat EPS estimates 67% of the time across 3 reported quarters (2 beats, 1 misses). Data sourced from SEC EDGAR.
| Quarter | EPS Estimate | EPS Actual | Surprise | Result |
|---|---|---|---|---|
| Q22026 FY2026 | $-0.11 | $-0.16 | -45.5% | Miss |
| Q12026 FY2026 | $-0.16 | $-0.14 | +12.5% | Beat |
| Q42025 FY2025 | $-0.13 | $-0.12 | +7.7% | Beat |
Back to TLSI overview · TLSI holders · TLSI KPIs
Data sourced from U.S. SEC EDGAR filings. Not personalized investment advice.